Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR): Current price $11.99
Baird believes Optimer Pharmaceuticals, Inc. remains an attractive investment and estimates a buyer can get a deal done for under $1 billion in cash. The firm noted the departure of the Chief Executive Officer and General Counsel, due to potential compliance issues, related to a share grant at one of their Taiwanese subsidiaries. Baird said it is impossible to quantify the value of the liability at this point, but expects it to be a point of leverage for a suitor, rather than a deal breaker. Shares are Outperform rated with a $16 price target.